Premium
Respiratory acute discharge service: a hospital in the home programme for chronic obstructive pulmonary disease exacerbations (RADS study)
Author(s) -
Samaranayake Chinthaka B.,
Neill Jane,
Bint Michael
Publication year - 2020
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14646
Subject(s) - medicine , interquartile range , exacerbation , emergency medicine , population , pediatrics , environmental health
Background Respiratory Acute Discharge Service (RADS) is a novel early discharge service with nurse‐led community based recovery in selected patients with acute exacerbations of chronic obstructive pulmonary disease. Aim This pilot study aimed to determine the efficacy and safety of the programme in an Australian tertiary hospital. Methods All patients who were recruited to RADS at Sunshine Coast University Hospital over a 6 months period from June to November 2018 were included. The co‐primary outcomes were length of hospital days saved and rate of readmission within 30 days from discharge. Results A total of 166 patients (median age 74 years (interquartile range 70–80 years)) was recruited to the programme over the study period. The mean forced expiratory volume in one second (FEV1%) of the patients was 42% (standard deviation 19). The median length‐of‐stay prior to discharge on the RADS programme was 1 day (range 0–5), compared to a previous average of 5.8 days in our health service. Patients were on the programme for a median of 4 days (range 1–6). A total of 613 hospital bed days was saved over the study period, with significant cost savings. Forty‐one (24.7%) patients represented to hospital within 30 days, the majority (64%) were due to recurrent symptoms. The rate of 30‐day all‐cause mortality for the study population was 1 (0.6%). Conclusion Early supported discharge care model with nurse‐led community based recovery after an acute exacerbation of chronic obstructive pulmonary disease in selected patients is safe, and has the potential to provide greater flow through the hospital systems with cost effective care.